文献速递前列腺癌

前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描淋巴结分期与扩大盆腔淋巴结清扫对淋巴结阳性前列腺癌患者的预后价值

The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
PubMed 文献 · BJU Int · 2022-09-17

研究纳入2017年1月至2020年12月期间接受机器人辅助根治性前列腺切除术(RARP)和扩大盆腔淋巴结清扫(ePLND)后病理证实盆腔淋巴结转移(pN1)的145例患者。术前PSMA PET/CT未见盆腔淋巴结转移(miN0)者的中位生化无进展生存期为13.7个月,而miN1者为7.9个月(P=0.006)。多变量Cox回归显示,肿瘤阳性淋巴结数量(>2 vs 1-2:HR 1.97;P=0.005)和最大淋巴结转移灶直径(HR 1.12;P<0.001)是生化进展的显著独立预测因素。

要点

  • 术前PSMA PET/CT提示盆腔淋巴结转移(miN1)者术后生化进展风险高于miN0者,中位生化无进展生存期分别为7.9个月 vs 13.7个月(P=0.006)。
  • 肿瘤阳性淋巴结数量>2个 vs 1-2个是生化进展的独立预测因素(HR 1.97;P=0.005)。
  • 最大淋巴结转移灶直径是生化进展的独立预测因素(HR 1.12;P<0.001)。

核心结论

  • 术前PSMA影像怀疑盆腔淋巴结转移(miN1)、肿瘤阳性淋巴结>2个以及最大淋巴结转移灶直径较大的患者,术后生化疾病进展风险显著增加。

研究设计与样本

  • 纳入2017年1月至2020年12月期间接受机器人辅助根治性前列腺切除术(RARP)和扩大盆腔淋巴结清扫(ePLND)后病理确诊盆腔淋巴结转移(pN1)的全部患者,共145例。
  • 采用多变量Cox回归分析评估RARP术后生化进展的预测因素,纳入变量包括肿瘤阳性淋巴结数量、最大淋巴结转移灶直径和结外延伸。

主要发现

  • 术前PSMA PET/CT为miN0的患者中位生化无进展生存期为13.7个月,miN1者为7.9个月(P=0.006)。
  • 多变量Cox回归显示,肿瘤阳性淋巴结数量>2 vs 1-2是生化进展的显著独立预测因素(HR 1.97;P=0.005)。
  • 最大淋巴结转移灶直径是生化进展的显著独立预测因素(HR 1.12;P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether patients with suspected pelvic lymph node metastases (molecular imaging [mi] N1) on staging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) had a different oncological outcome compared to those in whom the PSMA PET/CT did not reveal any pelvic lymph node metastases (miN0). PATIENTS AND METHODS: All patients with pelvic lymph node metastatic (pN1) disease after robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND) between January 2017 and December 2020 were included. To assess predictors of biochemical progression of disease after RARP, a multivariable Cox regression analysis was performed, including number of tumour-positive lymph nodes, diameter of the largest nodal metastasis, and extranodal extension. RESULTS: In total, 145 patients were diagnosed with pN1 disease after ePLND. The median biochemical progression-free survival in patients with miN0 on PSMA PET/CT was 13.7 months, compared to 7.9 months in patients with miN1 disease (P = 0.006). On multivariable Cox regression analysis, both number of tumour-positive lymph nodes (>2 vs 1-2: hazard ratio [HR] 1.97; P = 0.005) and diameter of the largest nodal metastasis (HR 1.12; P < 0.001) were significant independent predictors of biochemical progression of disease. CONCLUSION: Patients in whom pelvic lymph node metastases were suspected on preoperative PSMA imaging (miN1), patients diagnosed with >2 tumour-positive lymph nodes, and patients with a larger diameter of the largest nodal metastasis had a significantly increased risk of biochemical disease progression after surgery.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Meijer D, Ettema RH, van Leeuwen PJ, et al. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. BJU Int. 2022. PMID: 36069585. doi:10.1111/bju.15881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。